Branched multi-functional macromonomers and uses thereof
Disclosed are methods, compositions, reagents, systems, and kits to prepare and utilize branched multi-functional macromonomers, which contain a ring-opening metathesis polymerizable norbornene group, one or more reactive sites capable of undergoing click chemistry, and a terminal acyl group capable of undergoing a coupling reaction; branched multi-cargo macromonomers; and the corresponding polymers are disclosed herein. Various embodiments show that the macromonomers and polymers disclosed herein display unprecedented control of cargo loading of agents. These materials have the potential to be utilized for the treatment of diseases and conditions such as cancer and hypertension.
1. A macromonomer of Formula (I):
or a salt thereof, wherein:
each instance of R A is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl;
a is an integer from 1 to 20, inclusive;
each instance of M is independently hydrogen or an agent, wherein each instance of the agent is independently a therapeutic agent, a diagnostic agent, or a prophylactic agent;
each instance of m is independently an integer from 1 to 10, inclusive;
each instance of L is independently substituted or unsubstituted, C 1-200 alkylene, substituted or unsubstituted, C 2-200 alkenylene, substituted or unsubstituted, C 2-200 alkynylene, substituted or unsubstituted, C 2-200 heteroalkylene, substituted or unsubstituted, C 2-200 heteroalkenylene, or substituted or unsubstituted, C 2-200 heteroalkynylene, wherein:
optionally one or more carbons in each instance of the substituted or unsubstituted, C 1-200 alkylene, substituted or unsubstituted, C 2-200 alkenylene, substituted or unsubstituted, C 2-200 alkynylene, substituted or unsubstituted, C 2-200 heteroalkylene, substituted or unsubstituted, C 2-200 heteroalkenylene, and substituted or unsubstituted, C 2-200 heteroalkynylene are independently replaced with substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
optionally one or more heteroatoms in each instance of the substituted or unsubstituted, C 2-200 heteroalkylene, substituted or unsubstituted, C 2-200 heteroalkenylene, and substituted or unsubstituted, C 2-200 heteroalkynylene are independently replaced with substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
provided that when each instance of M is hydrogen, at least one instance of -L(M) m comprises a click-chemistry handle;
each instance of R B is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl;
each instance of b is independently an integer from 1 to 20, inclusive;
e is an integer from 1 to 10, inclusive; and
X is OR C or N(R D ) 2 , wherein:
R C is hydrogen, substituted or unsubstituted, C 1-1000 alkyl, substituted or unsubstituted, C 2-1000 alkenyl, substituted or unsubstituted, C 2-1000 alkynyl, substituted or unsubstituted, C 1-1000 heteroalkyl, substituted or unsubstituted, C 2-1000 heteroalkenyl, substituted or unsubstituted, C 2-1000 heteroalkynyl, an oxygen protecting group, or a leaving group; and
each instance of R D is independently hydrogen, substituted or unsubstituted, C 1-1000 alkyl, substituted or unsubstituted, C 2-1000 alkenyl, substituted or unsubstituted, C 2-1000 alkynyl, substituted or unsubstituted, C 1-1000 heteroalkyl, substituted or unsubstituted, C 2-1000 heteroalkenyl, substituted or unsubstituted, C 2-1000 heteroalkynyl, or a nitrogen protecting group, or two R D are taken together to form a substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl moiety.
2. The macromonomer of claim 1 , or a salt thereof, wherein at least one instance of L is substituted or unsubstituted, C 2-200 heteroalkylene, wherein one or more carbons and/or one or more heteroatoms, of the substituted or unsubstituted, C 2-200 heteroalkylene, are independently replaced with
wherein the nitrogen atom labeled with “*” is closer to the attachment point labeled with “**” than the attachment point labeled with “***”.
3. The macromonomer of claim 1 , or a salt thereof, wherein at least two instances of M that are agents are different from each other.
4. The macromonomer of claim 1 , or a salt thereof, wherein at least one instance of m is 2, 3, 4, or 5.
5. A method of preparing a macromonomer of claim 1 , or a salt thereof, comprising coupling a compound of the formula:
or a salt thereof, with a compound of the formula: HOR C or HN(R D ) 2 , or a salt thereof.
6. A polymer prepared by polymerizing a macromonomer of claim 1 , or a salt thereof, in the presence of a metathesis catalyst.
7. The polymer of claim 6 , wherein the polymer is prepared by polymerizing a first instance of the macromonomer, or a salt thereof, and a second instance of the macromonomer, or a salt thereof, in the presence of a metathesis catalyst, wherein at least one instance of M of the first instance of the macromonomer is different from at least one instance of M of the second instance of the macromonomer.
8. A method of preparing a polymer comprising polymerizing a macromonomer of claim 1 , or a salt thereof, in the presence of a metathesis catalyst.
9. The method of claim 8 comprising polymerizing a first instance of the macromonomer, or a salt thereof, and a second instance of the macromonomer, or a salt thereof, in the presence of a metathesis catalyst, wherein at least one instance of M of the first instance of the macromonomer is different from at least one instance of M of the second instance of the macromonomer.
10. A pharmaceutical composition comprising a polymer of claim 6 , and optionally a pharmaceutically acceptable excipient, wherein at least one instance of M is a therapeutic agent, a diagnostic agent, or a prophylactic agent.
11. A kit comprising:
a polymer of claim 6 ; and
instructions for using the polymer.
12. A method of delivering a therapeutic agent, a diagnostic agent, or a prophylactic agent to a subject comprising administering to the subject a polymer of claim 6 , wherein at least one instance of M is a therapeutic agent, a diagnostic agent, or a prophylactic agent.
13. A method of delivering a therapeutic agent, a diagnostic agent, or a prophylactic agent to a cell comprising contacting the cell with a polymer of claim 6 , wherein at least one instance of M is a therapeutic agent, a diagnostic agent, or a prophylactic agent.
14. A method of treating a disease or condition in a subject in need thereof comprising administering to or implanting in the subject in need thereof a therapeutically effective amount of:
a polymer of claim 6 ;
wherein at least one instance of M is a therapeutic agent.
15. A method of diagnosing a disease or condition in a subject comprising administering to or implanting in the subject a diagnostically effective amount of:
a polymer of claim 6 ;
wherein at least one instance of M is a diagnostic agent.
16. The macromonomer of claim 1 , or a salt thereof, wherein each instance of R A is hydrogen.
17. The macromonomer of claim 1 , or a salt thereof, wherein a is 4, 5, or 6.
18. The macromonomer of claim 1 , or a salt thereof, wherein at least one instance of -L(M) m is —(CH 2 ) p —C≡CH, wherein each instance of p is independently an integer from 1 to 10, inclusive.
19. The macromonomer of claim 1 , or a salt thereof, wherein each instance of M is hydrogen, and each instance of the click-chemistry handle is —C≡CH.
20. The macromonomer of claim 1 , or a salt thereof, wherein at least one instance of M is a therapeutic agent, a diagnostic agent, or a prophylactic agent.
21. The macromonomer of claim 1 , or a salt thereof, wherein at least one instance of M is an anti-cancer agent.
22. The macromonomer of claim 1 , or a salt thereof, wherein each instance of m is 1.
23. The macromonomer of claim 1 , or a salt thereof, wherein each instance of R B is hydrogen.
24. The macromonomer of claim 1 , or a salt thereof, wherein each instance of b is independently 2, 3, or 4.
25. The macromonomer of claim 1 , or a salt thereof, wherein e is 2, 3, or 4.
26. The macromonomer of claim 1 , or a salt thereof, wherein X is N(R D ) 2 .
27. The macromonomer of claim 26 , or a salt thereof, wherein at least one instance of R D is substituted or unsubstituted, C 50-1000 heteroalkyl.
28. The macromonomer of claim 1 , or a salt thereof, wherein the macromonomer is of the formula:
wherein e is an integer from 2 to 10, inclusive.
29. The macromonomer of claim 1 , or a salt thereof, wherein the macromonomer is of the formula:
wherein:
each instance of p is independently an integer from 1 to 10, inclusive; and
e is an integer from 2 to 10, inclusive.
30. The macromonomer of claim 1 , or a salt thereof, wherein the macromonomer is of the formula:
31. The method of claim 14 , wherein the disease or condition is cancer, and at least one instance of M is an anti-cancer agent.